BioProcess Insider Daily - Biotech Week Boston

Read More
Vertex adds Lonza to cautious Casgevy commercial network

Vertex says finding the sweet spot in manufacturing capacity is key to ensuring the successful rollout of sickle cell gene therapy Casgevy (exagamglogene autotemcel).

Global MarketsWhite House OSTP: ‘Whether Harris or Trump, biomanufacturing is bipartisan’

A President Biden Executive Order supporting homegrown biomanufacturing will remain in place whoever wins in November, White House OSTP assistant director Sarah Glaven told Biotech Week Boston delegates.

Facilities & CapacityResilience opens doors to showcase former Sanofi plant to BWB delegates

CDMO Resilience hosted visitors at its Boston manufacturing site during Biotech Week Boston.

Upstream & Downstream ProcessingUnderstanding scope is key to tackling bioproduction tech challenges, say experts

Defining industry-wide problems and collaboratively solving them remain key for the industry, according to delegates discussing technology implementation at Biotech Week Boston.

Latest Issue

Accurate volume measurement
Special Report

From Pipettes to Infusion Pumps: Volume Accuracy in Regulated Industries and Its Critical Impact

Archive

Special Reports

Thermo Special Report Cover
Sponsored Content

As the monoclonal-antibody (mAb) market continues to grow, it is becoming increasingly important for pharmaceutical and biotech companies to accelerate process development and establish a scalable manufacturing process capable of achieving high titers and consistent product quality. Central to this is a cell culture media and feed system that can provide the required nutrients for optimal cell growth, viability, and function, as well as facilitate a seamless transition from development to clinical and commercial manufacturing. However, choosing an appropriate system can be a complex and time-consuming process, often requiring the evaluation of multiple medium and feed options. Platform systems, consisting of a medium and complementary feed developed for a specific cell line and application, have emerged as a valuable option for developers to help simplify selection and increase scale-up efficiency. To meet the need for high-performance platform mAb manufacturing solutions, Thermo Fisher Scientific has dev...

Sponsored Content

Precision in volume delivery is critically important for both the biopharmaceutical and medical device industries. This special report discusses how accurate volume measurement affects patient safety, product quality, and regulatory compliance. Sartorius emphasizes the roles that infusion pumps, laboratory pipettes, and quality control (QC) measures play in ensuring reliable and reproducible results. Register or Login and hit Download Now to get the full Special Report.

Ask the Expert Webcasts

WuXi XDC
Sponsored Content

This webcast features: Bingquan (Stuart) Wang, PhD, Senior Director, US-EU CMC Management, WuXi XDC. Antibody-drug conjugate (ADC), is one of the fastest growing fields in therapy for life-threatening diseases. Its novel mechanism of action, target for unmet serious diseases and significant therapeutic effect has led the expedited development and approval of several new ADC drugs. However, ADC development presents unique and serious challenges. The combination of a large molecule and a small molecule increases complexity and therefore slows down progress. Producing the native antibody and the drug and linker requires multiple processes, as does drug substance conjugation and drug product manufacturing. Additionally, various assays are essential to support manufacturing, characterization, and release and stability testing. Overcoming these hurdles requires advanced CMC expertise and innovative technology. Key Takeaways: Register or Login and hit Watch on Demand to view the recorded webcast now.

Sponsored Content

This webcast features: Hakyung Kim, Senior Scientist, Upstream Process Development & Dongyoung Park, Senior Scientist, Upstream Process Development, Samsung Biologics. Recent innovations in intensified fed-batch (IFB) processing have dramatically improved cell culture yields and scalability, offering a powerful solution for optimizing biopharmaceutical production. By incorporating the IFB approach, Samsung Biologics has developed a platform that optimizes crucial process parameters to maximize the productivity of cultured cell lines. Join Samsung Biologics for this webinar as they explore the latest advancements in IFB processing and discuss how our novel platform, S-Tensify™, ensures consistent quality and productivity in an increasingly complex production landscape. Key Takeaways: Register or Login and hit Watch on Demand to view the recorded webcast now.